Heart-First approach may shield lung cancer patients from treatment side effects

NCT ID NCT04980716

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Nov 18, 2025 · Last updated May 24, 2026 · Updated 23 times

Summary

This study tests whether early, specialized heart monitoring and care can reduce heart problems in people with advanced lung cancer who are getting chemoradiation and immunotherapy. About 524 adults with stage III non-small cell lung cancer will be randomly assigned to receive either standard care or early heart-focused care guided by a non-invasive heart monitor. The goal is to see if this approach improves survival and lowers the risk of serious heart side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

CARDIOVASCULAR COMPLICATION NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER